Screener
Vertex Pharmaceuticals VRTX Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Vertex Pharmaceuticals’s 8-K, filed August 3, 2026. Open the filing →
- Filed
- Aug 3, 2026, 4:09 PM EDT
- Accession
- 0000875320-26-000256
FAQ
- What is Vertex Pharmaceuticals's operating lease liabilities?
- Vertex Pharmaceuticals (VRTX) reported operating lease liabilities of $1.98B in Q2 2026.
- How has Vertex Pharmaceuticals's operating lease liabilities changed year-over-year?
- Vertex Pharmaceuticals's operating lease liabilities increased by 29.5% year-over-year, from $1.53B to $1.98B.
- What is the long-term trend for Vertex Pharmaceuticals's operating lease liabilities?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's operating lease liabilities has grown at a 39.4% compound annual growth rate (CAGR), from $350.5M to $1.85B.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Vertex Pharmaceuticals's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude